 |
| What are my chances of a sustained
response with PegIntron + Rebetol? |
|
| All
Patients |
61% |
All
"adherent" patients |
72% |
| Genotype 1 patients |
48% |
"Adherent"
Genotype 1 patients |
63% |
| Genotype 2/3
patients |
88% |
"Adherent"
Genotype 2/3 patients |
94% |
Genotype 1 patients
with low viral load |
73% |
Genotype 1 patients
with high viral load |
37% |
|
|
| What do I need to know about
PegIntron + Rebetol? |
|
|
YOU OR YOUR PARTNER SHOULD AVOID
BECOMING PREGNANT while taking PegIntron + Rebetol.
|
|
| If you or your partner are are pregnant,
you should not receive PegIntron + Rebetol. |
|
| Pregnancy should not be planned while you
or your partner are on therapy, or for 6 months after
therapy. If you or your partner become pregnant
while on therapy or during the 6 months after stopping
therapy, consult your doctor immediately. |
|
|
BOTH MALE AND FEMALE PATIENTS MUST USE
EFFECTIVE CONTRACEPTION during treatment, and for the 6
months after treatment is completed.
|
|
| You should discuss with your doctor how
you or your partner can prevent getting pregnant. |
|
|
PegIntron + Rebetol (ribavirin) Capsules cause
anemia, which is a decrease in the number of your red
blood cells.
|
|
| This can be dangerous, especially for
patients who already have heart or circulatory
(cardiovascular) problems. Talk with your doctor
before taking PegIntron + Rebetol therapy if you have ever had any
cardiovascular problems. |
|
|
|
|
| << Previous Page ||
Back To Top || Next Page >> |
|
